Coffee and Arterial Stiffness Evaluation (CASE)
Coffee and Arterial Stiffness: Effects on Chronic Coffee Intake on Markers of Vascular Function, Cardiometabolic and Liver Health
This study aims to investigate whether twelve weeks of daily coffee consumption can improve blood vessel elasticity (arterial stiffness) in adults typical of the UK population who are currently non-habitual coffee consumers. Additionally, the effects on cardiometabolic disease risk markers, liver health markers, cognitive function and inter-individual genetic variations in response to coffee consumption will be examined.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Coffee has gained interest for its role in the prevention of non-communicable diseases such as heart and liver disease. Observational studies have reported that regular coffee consumption (2-4 cups per day) is associated with reduced risk of cardiovascular disease, type 2 diabetes, and overall mortality. However, these observational studies do not prove direct causality, requiring the need for well-designed randomized controlled trials. Additionally, most evidence comes from habitual coffee drinkers, and there is limited understanding of whether introducing coffee to non-habitual consumers can provide similar health benefits, particularly in individuals that are typically reflective of the UK population.
This trial aims to provide direct causal evidence to the potential health effects of coffee consumption on risk markers for the development of cardiometabolic disease (such as type 2 diabetes, heart and liver diseases). To ensure the potential impact of habitual coffee consumption is minimised as a confounding factor, non-habitual coffee consumers (coffee-naïve) will be recruited. To maximise recruitment and adherence in the study, the coffee intervention is being provided in a tablet formulation (as opposed to a liquid drink formulation typical taken). In a previous pilot study conducted in 2025, the biological activity of the coffee tablet formulation is expected to be deemed bioequivalent compared to the liquid drink.
A 2-armed, double-blind, randomized controlled parallel trial will be conducted in participants that reflect the general population (estimated using UK representative data from the National Diet and Nutrition Survey). The primary outcome is the effect of coffee consumption on arterial stiffness (measured by cardio-ankle vascular index (CAVI)), an important prognostic marker of vascular aging and cardiovascular disease. Secondary outcomes will assess the impact of coffee consumption on cardiometabolic disease risk markers, liver health markers, cognitive function and genetic factors driving inter-individual response. This will be compared to a coffee-free control.
Study participation will require two visits to the Hugh Sinclair Unit of Human Nutrition (HSU), University of Reading, UK. For the first visit, participants will arrive having fasted overnight, consumed a standardised evening meal, and having followed lifestyle restrictions in the preceding days. Baseline anthropometric measures, blood pressure, CAVI measures, cognitive functions scores will be performed in addition to collecting a fasting blood sample (up to 50ml in total). Additionally, participants will be asked to provide a 24-hour urine sample during the same visit. At the end of the first study visit, participants will be randomised, stratified by age, gender and body-mass index (BMI), and receive their intervention bottles containing tablets to take on a daily basis over the 12-week study period. The second study visit will repeat the same procedures outlined at the end of 12 weeks.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Charlotte E Mills, PhD
- Numero di telefono: 7108 0118378
- Email: c.e.mills@reading.ac.uk
Backup dei contatti dello studio
- Nome: Kim G Jackson, PhD
- Numero di telefono: 5361 0118378
- Email: k.g.jackson@reading.ac.uk
Luoghi di studio
-
-
Berkshire
-
Reading, Berkshire, Regno Unito, RG6 6DZ
- Hugh Sinclair Unit of Human Nutrition
-
Contatto:
- Sandra Ilett
- Numero di telefono: 7771 0118378
- Email: nutritionvolunteers@reading.ac.uk
-
Sub-investigatore:
- Kim G Jackson, PhD
-
Sub-investigatore:
- Anisha Wijeyesekera, PhD
-
Sub-investigatore:
- TiJesu Akeredolu, MPharm
-
Sub-investigatore:
- Lolwa Alawadhi, MSc
-
Sub-investigatore:
- Altaf Farraj, MSc
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Males and females
- Aged between 40 to 75 years
- Low habitual coffee consumption (less than 3 cups per week) (over the past 4-week period)
- Body mass index (BMI) between 18.5-32.0kg/m^2 (inclusive)
- Total cholesterol ≤6.5 mmol/L
- Fasting triglycerides <1.7 mmol/L
- Fasting glucose ≤ 6.1 mmol/L
- Blood pressure 90/60 - 140/90 mmHg (inclusive)
Exclusion Criteria:
- Sensitivity to coffee or caffeine
- Regular consumption of caffeinated products or drinks; including tea, energy drinks or caffeine tablets (over 350 mg caffeine per week) or unwilling to stop drinking coffee during the intervention period
- Current smoking and vaping use
- Medical history of chronic diseases (cancer, hypertension, type 2 diabetes, ischaemic attacks and/or any other cardiovascular related diseases, gastro-intestinal disorders, hyperlipidaemia, kidney or liver disease)
- Haemoglobin <115 g/L for females or <130 g/L for males
- Prescribed any medication relating to the study outcome measures (such as blood pressure lowering, anti-inflammatories or blood thinners)
- Current use or past use of antibiotics within 6 months
- Drinking more than the recommended intake for alcohol (>14 units of alcohol per week)
- Current undertaking or planning to start a weight reducing regimen
- Taking any supplements (vitamins, minerals, prebiotics and probiotics)
- Any other medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (e.g. pacemaker)
- Parallel participation in another intervention study
- Pregnancy, planning a pregnancy in the next 6 months or breastfeeding
- NHS blood donation (470 ml) in the last 3 months
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Coffee
This group will consume 5.4g of a commercially available instant coffee, provided in a tablet formulation (9 tablets daily). |
Commercially available instant coffee (5.4g), will be provided as 9 tablets (equivalent to 3 tablets per cup, therefore total 3 cups daily). This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day. |
|
Comparatore placebo: Control
This group will consume a coffee-free control, provided in a tablet formulation (9 tablets daily). |
Coffee-free control (microcrystallinecellulose (non-active)) will be provided as 9 tablets. This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cardio-ankle vascular index
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Cardio-ankle vascular index (CAVI) score will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) and attachment of a PCG microphone (measuring heart sounds during the cardiac cycle) on the sternum using a VaSera VS-2000 device on study visits. No fixed scale range is present, lower scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fasting coffee bioactives concentrations and polyphenol metabolite concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of key coffee bioactives (e.g. caffeine, chlorogenic acids, trigonelline) and polyphenol metabolites will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry, concentration unit of measure (microgram per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting lipid profile concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum total cholesterol (TC), triacylglycerol, high-density lipoprotein cholesterol (HDL-C), non-esterified fatty acids and apolipoprotein B will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). Low-density cholesterol concentrations will be calculated from TC concentrations and HDL-C concentrations using the Friedewald formula. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting insulin concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum insulin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (IU per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting glucose concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum glucose will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (millimolar per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting Haemoglobin A1C concentrations of glycaemic control measures
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Haemoglobin (Hb) A1C will be measured from a fasting whole blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (%). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimate of insulin resistance
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the fasting glucose and insulin data. Scale range: <1 - 5+, lower scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimate of insulin sensitivity
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the fasting glucose and insulin data. Scale range: <0.25 - 0.45+, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting liver enzyme and function concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transferase (AST), gamma-glutamyl transferase (GGT) and total bilirubin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (unit per liter). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting concentrations of kidney function measures
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum uric acid and creatinine will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting concentrations of inflammatory markers
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum interleukin (IL) 1b, IL-6, high sensitivity C-reactive protein, tumour necrosis factor alpha, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (picogram per millilitre) |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting brain-derived neurotrophic factor concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum brain-derived neurotrophic factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting vascular endothelial growth factor concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Serum vascular endothelial growth factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting oxidised low density lipoprotein cholesterol concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of oxidised low density cholesterol will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting trimethylamine N-oxide concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of trimethylamine N-oxide will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting gut hormone concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of C-peptide, gastric inhibitory polypeptide, glucagon-like receptor-1 and ghrelin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via Luminex |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimated nitric oxide concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Plasma estimated concentrations of nitric oxide (nitrate and nitrite) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via chemiluminescence/LCMS. |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary metabolomics
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Untargeted metabolomics will be performed on pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary creatinine concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Urinary concentrations of creatinine will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via clinical chemistry analyser |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary F2-isoprostanes concentrations
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Urinary concentrations of F2-isoprostanes will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry. |
Week 0 (baseline), Week 12 (final visit)
|
|
Identification of gut microbiota composition
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Gut microbiome composition will be identified and assessed using RNA sequencing from a stool sample, provided on day prior to study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Cognitive function
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Assessment of cognitive function will be performed using Millisecond Inquisit 7 software on study visits. No fixed scale range is present, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Clinic blood pressure
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Blood pressure will be measured using a blood pressure monitor on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Ankle Brachial Index
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Ankle Brachial Index will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) using a VaSera VS-2000 device on study visits. Scale range: <0.5 - 1.4+, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Lean body mass
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Body lean mass will be measured by bioelectrical impedance using the Tanita scale on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Body fat percentage
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Body fat percentage will be measured by bioelectrical impedance using the Tanita scale on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Body-mass index
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Height will be measured using a stadiometer on the first study visit. Weight will be measured using the Tanita scale on both study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Hip and waist circumference
Lasso di tempo: Week 0 (baseline), Week 12 (final visit)
|
Hip and waist circumference will be measured using a non-stretch tape on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Abbe Davy, BSc, University of Reading
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- UREC 26/31
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All anonymised IPD that underlie results in a publication and analytical code for statistical analysis
Periodo di condivisione IPD
Anonymised data will be made available on reasonable request to the study Chief Investigator one year after manuscripts have been published.
Criteri di accesso alla condivisione IPD
For data sharing and preservation, anonymised IPD will be archived in the University of Reading Research Data Archive. Access will be overseen by the project Chief Investigator (Associate Professor Charlotte Mills).
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- CODICE_ANALITICO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .